The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis

Ruben Mesa, Susan Schwager, Deepti Radia, Andrea Cheville, Kebede Hussein, Joyce Niblack, Animesh D. Pardanani, David P. Steensma, Mark R. Litzow, Candido E. Rivera, John Camoriano, Srdan Verstovsek, Jeffrey Sloan, Claire Harrison, Hagop Kantarjian, Ayalew Tefferi

Research output: Contribution to journalArticle

134 Citations (Scopus)

Abstract

Quality of life (QoL) in patients with myelofibrosis (MF) is severely compromised by severe constitutional symptoms (i.e. fatigue, night sweats, fever, weight loss), pruritus, and symptoms from frequently massive hepatosplenomegaly. Given that no current instrument of patient reported outcomes (PRO) exists that covers the unique spectrum of symptomatology seen in MF patients, we sought to develop a new PRO instrument for MF patients for use in therapeutic clinical trials. Utilizing data from an international Internet-based survey of 458 patients with MF we created a 20-item instrument (MFSAF: Myelofibrosis Symptom Assessment Form) which measures the symptoms reported by >10% of MF patients and includes a measure of QoL. We subsequently validated the MFSAF in a prospective trial of MF patients involving patient and provider feedback, as well as comparison to other validated instruments used in cancer patients. The MFSAF results were highly correlated with other instruments, judged comprehensive and understandable by patients, and should be considered for evaluation of MF symptoms in therapeutic trials.

Original languageEnglish (US)
Pages (from-to)1199-1203
Number of pages5
JournalLeukemia Research
Volume33
Issue number9
DOIs
StatePublished - Sep 1 2009
Externally publishedYes

Fingerprint

Primary Myelofibrosis
Symptom Assessment
Quality of Life
Equipment and Supplies
Therapeutics
Sweat
Therapeutic Uses
Pruritus
Internet
Fatigue
Weight Loss
Fever
Clinical Trials

Keywords

  • Fatigue
  • Myelofibrosis
  • Myeloproliferative disorder
  • Primary myelofibrosis
  • Splenomegaly

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

The Myelofibrosis Symptom Assessment Form (MFSAF) : An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. / Mesa, Ruben; Schwager, Susan; Radia, Deepti; Cheville, Andrea; Hussein, Kebede; Niblack, Joyce; Pardanani, Animesh D.; Steensma, David P.; Litzow, Mark R.; Rivera, Candido E.; Camoriano, John; Verstovsek, Srdan; Sloan, Jeffrey; Harrison, Claire; Kantarjian, Hagop; Tefferi, Ayalew.

In: Leukemia Research, Vol. 33, No. 9, 01.09.2009, p. 1199-1203.

Research output: Contribution to journalArticle

Mesa, R, Schwager, S, Radia, D, Cheville, A, Hussein, K, Niblack, J, Pardanani, AD, Steensma, DP, Litzow, MR, Rivera, CE, Camoriano, J, Verstovsek, S, Sloan, J, Harrison, C, Kantarjian, H & Tefferi, A 2009, 'The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis', Leukemia Research, vol. 33, no. 9, pp. 1199-1203. https://doi.org/10.1016/j.leukres.2009.01.035
Mesa, Ruben ; Schwager, Susan ; Radia, Deepti ; Cheville, Andrea ; Hussein, Kebede ; Niblack, Joyce ; Pardanani, Animesh D. ; Steensma, David P. ; Litzow, Mark R. ; Rivera, Candido E. ; Camoriano, John ; Verstovsek, Srdan ; Sloan, Jeffrey ; Harrison, Claire ; Kantarjian, Hagop ; Tefferi, Ayalew. / The Myelofibrosis Symptom Assessment Form (MFSAF) : An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. In: Leukemia Research. 2009 ; Vol. 33, No. 9. pp. 1199-1203.
@article{f871977e752e486c911772510f6d46fc,
title = "The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis",
abstract = "Quality of life (QoL) in patients with myelofibrosis (MF) is severely compromised by severe constitutional symptoms (i.e. fatigue, night sweats, fever, weight loss), pruritus, and symptoms from frequently massive hepatosplenomegaly. Given that no current instrument of patient reported outcomes (PRO) exists that covers the unique spectrum of symptomatology seen in MF patients, we sought to develop a new PRO instrument for MF patients for use in therapeutic clinical trials. Utilizing data from an international Internet-based survey of 458 patients with MF we created a 20-item instrument (MFSAF: Myelofibrosis Symptom Assessment Form) which measures the symptoms reported by >10{\%} of MF patients and includes a measure of QoL. We subsequently validated the MFSAF in a prospective trial of MF patients involving patient and provider feedback, as well as comparison to other validated instruments used in cancer patients. The MFSAF results were highly correlated with other instruments, judged comprehensive and understandable by patients, and should be considered for evaluation of MF symptoms in therapeutic trials.",
keywords = "Fatigue, Myelofibrosis, Myeloproliferative disorder, Primary myelofibrosis, Splenomegaly",
author = "Ruben Mesa and Susan Schwager and Deepti Radia and Andrea Cheville and Kebede Hussein and Joyce Niblack and Pardanani, {Animesh D.} and Steensma, {David P.} and Litzow, {Mark R.} and Rivera, {Candido E.} and John Camoriano and Srdan Verstovsek and Jeffrey Sloan and Claire Harrison and Hagop Kantarjian and Ayalew Tefferi",
year = "2009",
month = "9",
day = "1",
doi = "10.1016/j.leukres.2009.01.035",
language = "English (US)",
volume = "33",
pages = "1199--1203",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "9",

}

TY - JOUR

T1 - The Myelofibrosis Symptom Assessment Form (MFSAF)

T2 - An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis

AU - Mesa, Ruben

AU - Schwager, Susan

AU - Radia, Deepti

AU - Cheville, Andrea

AU - Hussein, Kebede

AU - Niblack, Joyce

AU - Pardanani, Animesh D.

AU - Steensma, David P.

AU - Litzow, Mark R.

AU - Rivera, Candido E.

AU - Camoriano, John

AU - Verstovsek, Srdan

AU - Sloan, Jeffrey

AU - Harrison, Claire

AU - Kantarjian, Hagop

AU - Tefferi, Ayalew

PY - 2009/9/1

Y1 - 2009/9/1

N2 - Quality of life (QoL) in patients with myelofibrosis (MF) is severely compromised by severe constitutional symptoms (i.e. fatigue, night sweats, fever, weight loss), pruritus, and symptoms from frequently massive hepatosplenomegaly. Given that no current instrument of patient reported outcomes (PRO) exists that covers the unique spectrum of symptomatology seen in MF patients, we sought to develop a new PRO instrument for MF patients for use in therapeutic clinical trials. Utilizing data from an international Internet-based survey of 458 patients with MF we created a 20-item instrument (MFSAF: Myelofibrosis Symptom Assessment Form) which measures the symptoms reported by >10% of MF patients and includes a measure of QoL. We subsequently validated the MFSAF in a prospective trial of MF patients involving patient and provider feedback, as well as comparison to other validated instruments used in cancer patients. The MFSAF results were highly correlated with other instruments, judged comprehensive and understandable by patients, and should be considered for evaluation of MF symptoms in therapeutic trials.

AB - Quality of life (QoL) in patients with myelofibrosis (MF) is severely compromised by severe constitutional symptoms (i.e. fatigue, night sweats, fever, weight loss), pruritus, and symptoms from frequently massive hepatosplenomegaly. Given that no current instrument of patient reported outcomes (PRO) exists that covers the unique spectrum of symptomatology seen in MF patients, we sought to develop a new PRO instrument for MF patients for use in therapeutic clinical trials. Utilizing data from an international Internet-based survey of 458 patients with MF we created a 20-item instrument (MFSAF: Myelofibrosis Symptom Assessment Form) which measures the symptoms reported by >10% of MF patients and includes a measure of QoL. We subsequently validated the MFSAF in a prospective trial of MF patients involving patient and provider feedback, as well as comparison to other validated instruments used in cancer patients. The MFSAF results were highly correlated with other instruments, judged comprehensive and understandable by patients, and should be considered for evaluation of MF symptoms in therapeutic trials.

KW - Fatigue

KW - Myelofibrosis

KW - Myeloproliferative disorder

KW - Primary myelofibrosis

KW - Splenomegaly

UR - http://www.scopus.com/inward/record.url?scp=67549104035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67549104035&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2009.01.035

DO - 10.1016/j.leukres.2009.01.035

M3 - Article

C2 - 19250674

AN - SCOPUS:67549104035

VL - 33

SP - 1199

EP - 1203

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 9

ER -